China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study of its Category 1 chemical drug XS-03. The study will assess the drug’s use in combination with FOLFOX or FOLFIRI plus bevacizumab for the treatment of RAS mutant metastatic colorectal cancer (CRC).
Drug Profile
XS-03 is an oral small molecule PLK1 inhibitor. It exerts anti-tumor effects by inhibiting tumor cell proliferation and promoting tumor cell apoptosis through the inhibition of cell cycle regulatory factors and induction of mitotic arrest. Mechanistically, XS-03 has synthetic lethality with KRAS mutations and has demonstrated a good inhibitory effect on colorectal cells carrying KRAS mutations. The drug has already entered clinical trials in China for the treatment of RAS mutant advanced solid tumors as a monotherapy.-Fineline Info & Tech
Leave a Reply